Since the trial results I have been watching quietly and patiently assessing the situation
and I have lost my confidence in the ability of IPIX to survive and thrive.
We all know that the powers that be have obviously been squelching
theraputics in favor of vaccine mandates and passports.We have seen this not only on currently
available products but also in the "slow walking" that has been exerted on trials as well as
the "favoritism" extended to large players.
That's why I was skeptable with the IPIX trial, Leo, his nephew and now their results.
Still,Bril is a major antiviral regardless of Leo's ethic with massive profit potantial.
Same with B in gastric applications,dermatology,etc.Nothing has changed.
(And don't even think of forgetting Kevetrin or Purisol)
Hopefully I'm not speaking too soon but I notice NO CHANGES IN MGT.and PERSONNEL/Dr.Degrado/BOD - who have been great at maximizing their own pockets at shareholder expense
Then the statement in the last PR:
"As discussed previously, the Company remains focused on developing Brilacidin as a novel therapy for Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis,
and also has plans to initiate Phase 3 testing of Brilacidin as an oral rinse treatment for Oral Mucositis
(OM) in head and neck cancer patients. Drug product development is ongoing with specialized Contract
Development and Manufacturing Organizations (CDMOs) responsible for refining the respective Brilacidin
formulation. The IBD and OM clinical indications represent large areas of unmet need, with significant
addressable commercial markets. And don't forget that blockbuster Purisol!
Elsewhere, Innovation management is engaged in discussions potentially to acquire rights to new pipeline
assets, as well as to enter into new licensing agreements. The Company plans to provide updates on these
matters as warranted. There is no guarantee, implied or otherwise, that such matters will result
in the execution of definitive agreements". Simply put Leo has done a great job
All my posts are rated pro
